Developer docs
API playgroundTry for free, no card

Search company profiles

Biocytogen

Full company profile

uuid000066v

Namestring
Biocytogen
Legal namestring
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Websiteurl
biocytogen.com
Company typeenum
Public
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery platforms, humanized mouse models, preclinical CRO services, gene editing technologies, antibody drug conjugates
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Medical Laboratories8071
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody Drug Discovery and Preclinical Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Platform Licensing
TypeLicensing Royalties
Description

Licensing of proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR) to pharmaceutical and biotech partners for internal R&D programs. Partners gain access to fully human antibody discovery capabilities in exchange for licensing fees.

biocytogen.com
2Milestone Payments
TypeLicensing Royalties
Description

Development and regulatory milestone payments triggered by partner achievements such as IND clearances, clinical trial phases, and approvals. Example: $5M milestone payment from IDEAYA for first patient dosed in Phase 1 trial.

biocytogen.com
3Royalty on Product Sales
TypeLicensing Royalties
Description

Ongoing royalty payments based on future product sales from therapeutics developed using licensed platforms.

biocytogen.com
4Preclinical Services
TypeProfessional Services
Description

Fee-for-service preclinical pharmacology, gene-editing, and animal model services provided to pharmaceutical and biotech clients.

biocytogen.com
5Animal Model Sales
TypeOne Time License
Description

Sale of off-the-shelf and custom genetically modified mouse models under the BioMice brand.

biocytogen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1BioMice
Description

Sub-brand for off-the-shelf animal and cell models, including humanized mouse models and custom gene-edited models for preclinical research.

biocytogen.com
+3 more records
Core offering1 text field

Biocytogen provides integrated antibody drug discovery solutions combining proprietary RenMice humanized mouse platforms (RenMab, RenLite, RenNano, RenTCR mimic), the AI-powered RenSuper Workstation, a 1M+ fully human antibody library, BioMice animal models, and preclinical pharmacology and gene editing services for global pharmaceutical and biotechnology clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 350+ therapeutic antibody agreements established globally as of December 2025
+2 more records
Product overview1 text field

Biocytogen offers a comprehensive integrated platform for antibody-based drug discovery spanning from target identification to IND submission. The core offering includes proprietary RenMice platforms (RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy-chain-only antibodies, RenTCR mimic™ for TCR discovery) combined with the AI-powered RenSuper™ Workstation for accelerated antibody discovery. The company provides a 1M+ fully human antibody library covering 1,000+ targets, supported by extensive preclinical services including gene editing, animal models (BioMice™), pharmacology studies, and AAALAC-accredited animal facility services. The platform enables generation of diverse antibody modalities including bispecific antibodies, ADCs, VHHs, and TCR mimic antibodies for global pharmaceutical and biotechnology partners.

Product and service11 records
1RenMab Platform
CategoryAntibody Discovery Platform
Description

Fully human monoclonal antibody discovery platform using mice with complete replacement of murine variable regions by full human heavy and kappa light chain V(D)J loci in situ; produces higher antibody diversity with normal immune system function comparable to wild-type mice, for pharmaceutical and biotechnology antibody discovery programs.

2RenLite Platform
CategoryAntibody Discovery Platform
Description

Bispecific and multispecific antibody discovery platform replacing murine heavy chain variable regions with human ones while using only one common kappa light chain, eliminating chain mispairing and enabling efficient assembly of bispecific antibodies and bispecific ADCs for partners developing multispecific therapeutics.

3RenNano Platform
CategoryAntibody Discovery Platform
Description

Fully human heavy chain-only antibody (HCAb) and VHH discovery platform containing complete human heavy chain variable genes with modified mouse constant regions, generating HCAbs with nM-level binding affinity independent of light chains, ideal for bispecific/multispecific antibodies, ADCs and CAR cell therapies.

4RenTCR mimic Platform
CategoryAntibody Discovery Platform
Description

TCR mimic antibody discovery platform modified to express human leukocyte antigen (HLA) genes, enabling high-throughput screening of antibodies with high specificity and affinity against intracellular tumor antigens that are inaccessible to conventional antibody approaches.

5RenSuper Workstation
CategoryAntibody Discovery Platform
Description

AI-powered antibody discovery platform providing off-the-shelf access to an experimentally validated library of fully human therapeutic antibody sequences paired with a fully automated high-throughput antibody manufacturing automation center, designed to accelerate antibody identification, validation and production for pharmaceutical and biotechnology partners.

6BioMice Animal Models
CategoryAnimal Models and Cell Lines
Description

Off-the-shelf and custom genetically engineered animal models including humanized immune checkpoint mouse models, immunodeficient rodent models, knockout models, disease-specific models, and engineered cell lines, used by researchers for preclinical drug evaluation, target validation and mechanistic studies.

7Preclinical Pharmacology Services
CategoryPreclinical CRO Services
Description

Comprehensive in vivo, ex vivo, and in vitro pharmacology capabilities including drug efficacy evaluation, pharmacodynamic (PD) and pharmacokinetic (PK) studies, biomarker response assessment, and non-GLP toxicity studies for pharmaceutical and biotechnology clients progressing drug candidates toward IND filing.

8Gene Editing Services
CategoryPreclinical CRO Services
Description

Custom gene editing services including conventional knockout/knockin, conditional knockout/knockin, point mutation knockin, Rosa26 locus knockin, tag/reporter genes, and Tol2 transgenic mouse models, using Biocytogen's proprietary gene editing technologies for academic, biotech and pharmaceutical researchers.

9Fully Human Antibody Library (1M+ sequences)
CategoryAntibody Discovery Asset Library
Description

Library of over 1 million fully human antibody sequences against more than 1,000 targets, including 30+ dual-TAA targeting bispecific ADCs, 200+ tumor-associated antigen projects, 30+ autoimmune projects, 10+ TCR mimic projects, and 1,500+ VHH antibody projects, offered to partners for in-licensing and co-development.

10RenMice HiTS Platform
CategoryAntibody Discovery Platform
Description

Open collaborative antibody hit discovery project using RenMab mice with targeted genetic disruption to generate antibody hits against thousands of potential drug targets in partnership with global pharmaceutical and biotechnology collaborators.

11Animal Center Services
CategoryPreclinical CRO Services
Description

AAALAC-accredited animal facility services including breeding and colony management, cryopreservation, rederivation, microbial detection, and operational consulting for laboratory animal facilities, available to academic and industry researchers.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Sihuan Pharmaceutical Holdings Group
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Strategic partnership to develop innovative antibody-based therapeutics across multiple disease areas including weight loss treatments. Biocytogen contributes its fully human antibody discovery platform including target-humanized mouse models and AI-driven antibody discovery, while Sihuan provides drug development, manufacturing, and commercialization capabilities. Collaboration aims to advance molecules including bispecific antibodies, ADCs, VHHs, and TCR-based therapeutics.

financialpost.com
2Taisho Pharmaceutical Co., Ltd.
Strategic tierStandardTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-30
Description

Platform license agreement granting Taisho access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody discovery platform for Taisho's internal R&D programs. Taisho will use RenNano mice to enable generation and screening of fully human HCAbs in vivo for next-generation VHH-based antibody modalities including bispecific antibodies, ADCs, and in vivo CAR-T therapies.

financialpost.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Partnership for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate for solid tumors. Biocytogen developed the bispecific antibody platform licensed to NEOK Bio in 2024. FDA IND clearance received March 2026 with Phase 1 trial planned for Q2 2026. Initial data expected in 2027.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Strategic collaboration to develop cutting-edge cell therapies for difficult-to-treat cancers. Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets while Moonlight Bio leads preclinical development of resulting cell therapies. Partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies to address solid tumor limitations.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-28
Description

Option and license agreement for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed to IDEAYA in July 2024. First patient dosed in Phase 1 trial February 2026 triggered $5 million milestone payment to Biocytogen. IDEAYA estimates 30-40% co-expression of both targets across major solid tumors.

Strategic tierStandardTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Expanded strategic collaboration to enhance India's biopharma ecosystem by improving access to advanced biomedical research tools. Expanded alliance adds pharmacology services, gene-edited cell line licensing, and distribution to existing partnership providing Biocytogen's BioMice humanized and engineered research models to Indian researchers.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Expanded collaboration through option-based evaluation framework for first-in-class bispecific and dual-payload ADCs (BsAD2C). Agreement enables Acepodia to evaluate and obtain exclusive worldwide license for two bispecific ADC programs. Combines Biocytogen's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Atreca
TypeEmerging player
Description

Clinical-stage biotech with an immune repertoire capture platform for antibody discovery. Comparable as an emerging antibody discovery platform company leveraging novel approaches to identify therapeutic candidates for partner pipelines.

TypeBroad incumbent
Description

Developer of the VelocImmune humanized mouse platform, which pioneered fully human antibody generation from transgenic mice. The original and most established competitor to Biocytogen's RenMice platforms, with a much larger commercial pipeline built on the same discovery paradigm.

TypeDirect peer
Description

Biologics CRO/CDMO division of GenScript providing antibody discovery, gene synthesis, and preclinical services. Competitor offering similar preclinical CRO and antibody discovery services to pharma/biotech clients with overlapping capabilities in humanized antibodies and gene editing.

TypeDirect peer
Description

AI/computation-driven antibody discovery platform developing dynamic precision medicine therapeutics. Closely comparable to Biocytogen in combining computational antibody design with proprietary platforms, and competing for similar oncology-focused pharma partners.

TypeDirect peer
Description

Pioneer in bispecific antibody technology with the DuoBody platform and a deep pipeline of approved/partnership antibodies. Direct peer in bispecific antibody development, which is a core capability of Biocytogen's RenLite platform.

TypeOthers
Description

Synthetic biology and DNA synthesis company offering antibody libraries and discovery tools (Twist Biopharma). Adjacent infrastructure provider rather than direct competitor, but comparable as a supplier of enabling antibody discovery technology and libraries.

TypeBroad incumbent
Description

Global leading biologics CRO/CDMO with end-to-end discovery, development, and manufacturing services. Competitor in preclinical antibody discovery and a much larger incumbent that provides similar integrated services to pharma clients, including from a China base.

TypeDirect peer
Description

AI-powered antibody discovery platform that screens natural immune repertoires and partners with pharma on therapeutic development. Direct competitor to Biocytogen in offering fully human antibody discovery with a tech-forward platform and similar licensing + milestone + royalty revenue model.

TypeRegional player
Description

Clinical-stage biotech based in China developing bispecific and multispecific antibodies for oncology. Comparable as a regional player focused on the same bispecific antibody modality space that Biocytogen's RenLite platform addresses.

10Harbour BioMed
TypeDirect peer
Description

Biotechnology company developing fully human antibody therapeutics using its proprietary H2L2 and HCAb transgenic mouse platforms. Closely comparable to Biocytogen in business model, technology basis, and target customer segment of pharma partners seeking humanized antibody discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocytogen

Antibody Drug Discovery and Preclinical Research Servicesbiocytogen.com

Biocytogen firmographics

Firmographics
Name
Biocytogen
Legal name
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Website
https://biocytogen.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Biocytogen industry classification

Industry
Product category
Antibody Drug Discovery and Preclinical Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery platforms
  • Humanized mouse models
  • Preclinical CRO services
  • Gene editing technologies
  • Antibody drug conjugates

Where Biocytogen is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Biocytogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Platform Licensing: Licensing of proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR) to pharmaceutical and biotech partners for internal R&D programs. Partners gain access to fully human antibody discovery capabilities in exchange for licensing fees.
  2. Milestone Payments: Development and regulatory milestone payments triggered by partner achievements such as IND clearances, clinical trial phases, and approvals. Example: $5M milestone payment from IDEAYA for first patient dosed in Phase 1 trial.
  3. Royalty on Product Sales: Ongoing royalty payments based on future product sales from therapeutics developed using licensed platforms.
  4. Preclinical Services: Fee-for-service preclinical pharmacology, gene-editing, and animal model services provided to pharmaceutical and biotech clients.
  5. Animal Model Sales: Sale of off-the-shelf and custom genetically modified mouse models under the BioMice brand.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Biocytogen product offering

Product offering

Core offering

Biocytogen provides integrated antibody drug discovery solutions combining proprietary RenMice humanized mouse platforms (RenMab, RenLite, RenNano, RenTCR mimic), the AI-powered RenSuper Workstation, a 1M+ fully human antibody library, BioMice animal models, and preclinical pharmacology and gene editing services for global pharmaceutical and biotechnology clients.

Product overview

Biocytogen offers a comprehensive integrated platform for antibody-based drug discovery spanning from target identification to IND submission. The core offering includes proprietary RenMice platforms (RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy-chain-only antibodies, RenTCR mimic™ for TCR discovery) combined with the AI-powered RenSuper™ Workstation for accelerated antibody discovery. The company provides a 1M+ fully human antibody library covering 1,000+ targets, supported by extensive preclinical services including gene editing, animal models (BioMice™), pharmacology studies, and AAALAC-accredited animal facility services. The platform enables generation of diverse antibody modalities including bispecific antibodies, ADCs, VHHs, and TCR mimic antibodies for global pharmaceutical and biotechnology partners.

Differentiator

Problem solved

Functional benefit

Brands

  • BioMice: Sub-brand for off-the-shelf animal and cell models, including humanized mouse models and custom gene-edited models for preclinical research.
  • RenSuper Biologics
  • RenMice
  • RenMice HiTS Platform

Products and services

  • RenMab Platform Fully human monoclonal antibody discovery platform using mice with complete replacement of murine variable regions by full human heavy and kappa light chain V(D)J loci in situ; produces higher antibody diversity with normal immune system function comparable to wild-type mice, for pharmaceutical and biotechnology antibody discovery programs.
  • RenLite Platform Bispecific and multispecific antibody discovery platform replacing murine heavy chain variable regions with human ones while using only one common kappa light chain, eliminating chain mispairing and enabling efficient assembly of bispecific antibodies and bispecific ADCs for partners developing multispecific therapeutics.
  • RenNano Platform Fully human heavy chain-only antibody (HCAb) and VHH discovery platform containing complete human heavy chain variable genes with modified mouse constant regions, generating HCAbs with nM-level binding affinity independent of light chains, ideal for bispecific/multispecific antibodies, ADCs and CAR cell therapies.
  • RenTCR mimic Platform TCR mimic antibody discovery platform modified to express human leukocyte antigen (HLA) genes, enabling high-throughput screening of antibodies with high specificity and affinity against intracellular tumor antigens that are inaccessible to conventional antibody approaches.
  • RenSuper Workstation AI-powered antibody discovery platform providing off-the-shelf access to an experimentally validated library of fully human therapeutic antibody sequences paired with a fully automated high-throughput antibody manufacturing automation center, designed to accelerate antibody identification, validation and production for pharmaceutical and biotechnology partners.
  • BioMice Animal Models Off-the-shelf and custom genetically engineered animal models including humanized immune checkpoint mouse models, immunodeficient rodent models, knockout models, disease-specific models, and engineered cell lines, used by researchers for preclinical drug evaluation, target validation and mechanistic studies.
  • Preclinical Pharmacology Services Comprehensive in vivo, ex vivo, and in vitro pharmacology capabilities including drug efficacy evaluation, pharmacodynamic (PD) and pharmacokinetic (PK) studies, biomarker response assessment, and non-GLP toxicity studies for pharmaceutical and biotechnology clients progressing drug candidates toward IND filing.
  • Gene Editing Services Custom gene editing services including conventional knockout/knockin, conditional knockout/knockin, point mutation knockin, Rosa26 locus knockin, tag/reporter genes, and Tol2 transgenic mouse models, using Biocytogen's proprietary gene editing technologies for academic, biotech and pharmaceutical researchers.
  • Fully Human Antibody Library (1M+ sequences) Library of over 1 million fully human antibody sequences against more than 1,000 targets, including 30+ dual-TAA targeting bispecific ADCs, 200+ tumor-associated antigen projects, 30+ autoimmune projects, 10+ TCR mimic projects, and 1,500+ VHH antibody projects, offered to partners for in-licensing and co-development.
  • RenMice HiTS Platform Open collaborative antibody hit discovery project using RenMab mice with targeted genetic disruption to generate antibody hits against thousands of potential drug targets in partnership with global pharmaceutical and biotechnology collaborators.
  • Animal Center Services AAALAC-accredited animal facility services including breeding and colony management, cryopreservation, rederivation, microbial detection, and operational consulting for laboratory animal facilities, available to academic and industry researchers.

Quantifiable outcome

  • 350+ therapeutic antibody agreements established globally as of December 2025
  • +2 more outcomes

Companies that use Biocytogen

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Biocytogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Biocytogen partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major and standard.

  • Sihuan Pharmaceutical Holdings GroupmajorStrategic or Co-development Partner · 1 April 2026Strategic partnership to develop innovative antibody-based therapeutics across multiple disease areas including weight loss treatments. Biocytogen contributes its fully human antibody discovery platform including target-humanized mouse models and AI-driven antibody discovery, while Sihuan provides drug development, manufacturing, and commercialization capabilities. Collaboration aims to advance molecules including bispecific antibodies, ADCs, VHHs, and TCR-based therapeutics.
  • Taisho Pharmaceutical Co., Ltd.standardOEM/ Whitelabel/ Licensing Partner · 30 March 2026Platform license agreement granting Taisho access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody discovery platform for Taisho's internal R&D programs. Taisho will use RenNano mice to enable generation and screening of fully human HCAbs in vivo for next-generation VHH-based antibody modalities including bispecific antibodies, ADCs, and in vivo CAR-T therapies.
  • NEOK Bio, Inc.majorStrategic or Co-development Partner · 27 March 2026Partnership for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate for solid tumors. Biocytogen developed the bispecific antibody platform licensed to NEOK Bio in 2024. FDA IND clearance received March 2026 with Phase 1 trial planned for Q2 2026. Initial data expected in 2027.
  • Moonlight Bio, Inc.majorStrategic or Co-development Partner · 23 March 2026Strategic collaboration to develop cutting-edge cell therapies for difficult-to-treat cancers. Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets while Moonlight Bio leads preclinical development of resulting cell therapies. Partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies to address solid tumor limitations.
  • IDEAYA BiosciencesmajorStrategic or Co-development Partner · 28 February 2026Option and license agreement for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed to IDEAYA in July 2024. First patient dosed in Phase 1 trial February 2026 triggered $5 million milestone payment to Biocytogen. IDEAYA estimates 30-40% co-expression of both targets across major solid tumors.
  • GV Safety Assessment Platform (GVSAP)standardChannel Partner/ Reseller/ Distributor · 5 February 2026Expanded strategic collaboration to enhance India's biopharma ecosystem by improving access to advanced biomedical research tools. Expanded alliance adds pharmacology services, gene-edited cell line licensing, and distribution to existing partnership providing Biocytogen's BioMice humanized and engineered research models to Indian researchers.
  • AcepodiamajorStrategic or Co-development Partner · 9 January 2026Expanded collaboration through option-based evaluation framework for first-in-class bispecific and dual-payload ADCs (BsAD2C). Agreement enables Acepodia to evaluate and obtain exclusive worldwide license for two bispecific ADC programs. Combines Biocytogen's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Biocytogen competitors and assessment

Company assessment

Emerging players

  • Atreca: Clinical-stage biotech with an immune repertoire capture platform for antibody discovery. Comparable as an emerging antibody discovery platform company leveraging novel approaches to identify therapeutic candidates for partner pipelines.

Broad incumbents

  • Regeneron Pharmaceuticals: Developer of the VelocImmune humanized mouse platform, which pioneered fully human antibody generation from transgenic mice. The original and most established competitor to Biocytogen's RenMice platforms, with a much larger commercial pipeline built on the same discovery paradigm.
  • WuXi Biologics: Global leading biologics CRO/CDMO with end-to-end discovery, development, and manufacturing services. Competitor in preclinical antibody discovery and a much larger incumbent that provides similar integrated services to pharma clients, including from a China base.

Direct peers

  • GenScript ProBio: Biologics CRO/CDMO division of GenScript providing antibody discovery, gene synthesis, and preclinical services. Competitor offering similar preclinical CRO and antibody discovery services to pharma/biotech clients with overlapping capabilities in humanized antibodies and gene editing.
  • Adagene: AI/computation-driven antibody discovery platform developing dynamic precision medicine therapeutics. Closely comparable to Biocytogen in combining computational antibody design with proprietary platforms, and competing for similar oncology-focused pharma partners.
  • Genmab: Pioneer in bispecific antibody technology with the DuoBody platform and a deep pipeline of approved/partnership antibodies. Direct peer in bispecific antibody development, which is a core capability of Biocytogen's RenLite platform.
  • AbCellera Biologics: AI-powered antibody discovery platform that screens natural immune repertoires and partners with pharma on therapeutic development. Direct competitor to Biocytogen in offering fully human antibody discovery with a tech-forward platform and similar licensing + milestone + royalty revenue model.
  • Harbour BioMed: Biotechnology company developing fully human antibody therapeutics using its proprietary H2L2 and HCAb transgenic mouse platforms. Closely comparable to Biocytogen in business model, technology basis, and target customer segment of pharma partners seeking humanized antibody discovery.

Others

  • Twist Bioscience: Synthetic biology and DNA synthesis company offering antibody libraries and discovery tools (Twist Biopharma). Adjacent infrastructure provider rather than direct competitor, but comparable as a supplier of enabling antibody discovery technology and libraries.

Regional players

  • Phanes Therapeutics: Clinical-stage biotech based in China developing bispecific and multispecific antibodies for oncology. Comparable as a regional player focused on the same bispecific antibody modality space that Biocytogen's RenLite platform addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Biocytogen social profiles

Digital presence

Biocytogen compliance and trust

Trust signal

Compliance2 records

Biocytogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocytogen leadership team

Management profile

Number of profiles

Profiles3 records

Biocytogen subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Biocytogen funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocytogen M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocytogen

What does Biocytogen do?

Biocytogen provides integrated antibody drug discovery solutions combining proprietary RenMice humanized mouse platforms (RenMab, RenLite, RenNano, RenTCR mimic), the AI-powered RenSuper Workstation, a 1M+ fully human antibody library, BioMice animal models, and preclinical pharmacology and gene editing services for global pharmaceutical and biotechnology clients.

Is Biocytogen a public or private company?

Biocytogen is a public company. It is classified as public and is currently operating.

When was Biocytogen founded?

Biocytogen was founded in 2008. It employs 101 to 250 people.

Where is Biocytogen based?

Biocytogen is headquartered in Waltham, United States, in the North America region.

How does Biocytogen make money?

Five revenue lines are on record. Platform Licensing is the primary driver. The others are milestone Payments, royalty on Product Sales, preclinical Services and animal Model Sales.

Who are Biocytogen's main competitors?

Atreca is listed as an emerging player. Broad incumbents are Regeneron Pharmaceuticals and WuXi Biologics. Direct peers are GenScript ProBio, Adagene, Genmab, AbCellera Biologics and Harbour BioMed. Twist Bioscience is listed as an others. Phanes Therapeutics is listed as a regional player.

Does Biocytogen have an API?

No public API is recorded for Biocytogen.

What industry is Biocytogen in?

Biocytogen's product category is Antibody Drug Discovery and Preclinical Research Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyBiocytogen, Qilu Pharmaceutical sign agreement for VHH antibody moleculeBiocytogen Pharmaceuticals and Qilu Pharmaceutical signed a non-exclusive licensing agreement for a fully human VHH antibody developed via Biocytogen's RenNano platform. The deal includes an upfront payment and milestone payments tied to development, regulatory, and commercial objectives, with no further financial details disclosed.BioSpaceBiocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in NeuroscienceBiocytogen entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule. The deal includes an upfront payment and milestone payments, with future development modality to be determined. The collaboration expands Biocytogen's antibody assets across therapeutic areas.BioSpaceWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsWhitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6 million and cash of $190 million, funding operations into 2H 2028. The company continued Phase 1 enrollment for HWK-007 and HWK-016, with HWK-206 trial initiation planned for Q3 2026.PR NewswireWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsWhitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6 million and cash of $190 million as of June 30, 2026. The company continues Phase 1 trials for HWK-007 and HWK-016, with HWK-206 planned to initiate in Q3 2026. It also entered an option agreement with Hangzhou DAC and a collaboration with Biocytogen.South China Morning PostMainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals | South China Morning PostMainland Chinese institutional fund managers have been increasing their stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in cross-border licensing deals. E Fund Management took a 7 per cent stake in Biocytogen Pharmaceuticals while Fullgoal Fund and China Universal Asset Management also raised their holdings in multiple biotech firms including CSPC Pharmaceutical Group. The trend coincides with a $1.77 billion collaboration agreement between CSPC Pharmaceutical Group and AstraZeneca, with analysts noting multiple catalysts expected for the sector in the second half of the year.BioWorldBiocytogen Pharmaceuticals discloses new anti-DLL3/B7H3 ADCsBiocytogen Pharmaceuticals has prepared and tested new bispecific antibody-drug conjugates targeting B7-H3 and DLL3, linked to cytotoxic drugs. The ADCs are described as potentially useful for cancer treatment.Pharmaceutical TechnologyBiocytogen and Whitehawk partner to develop ADCsBiocytogen and Whitehawk Therapeutics have entered a global partnership to develop bispecific antibody-drug conjugates (BsADCs), with Biocytogen providing access to up to five bispecific antibodies through its RenLite platform and Whitehawk evaluating them alongside its own ADC linker-payload technology. If Whitehawk advances any resulting BsADC candidates, it will hold global rights and complete programme control, while Biocytogen receives an upfront payment plus eligibility for development, regulatory, and commercial milestone payments along with low single-digit royalties on net sales. The collaboration leverages Biocytogen's antibody generation capabilities and Whitehawk's expertise in ADC technologies to identify differentiated therapeutic candidates for cancer treatment.GurufocusBiocytogen and Whitehawk Therapeutics Enter Global CollaborationBiocytogen and Whitehawk Therapeutics have entered a global collaboration to develop bispecific antibody-drug conjugates (BsADC), with Biocytogen providing access to up to five bispecific antibodies from its RenLite® platform and Whitehawk evaluating them with its ADC linker-payload technologies. Whitehawk holds the option to advance resulting BsADC candidates and obtain global rights and full program control. Under the agreement, Biocytogen will receive an upfront payment, eligibility for development, regulatory, and commercial milestone payments, and low single-digit royalties on net sales.Stock TitanWhitehawk, Biocytogen strike BsADC collaborationBiocytogen and Whitehawk Therapeutics announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC), with Biocytogen providing up to five bispecific antibodies from its RenLite® platform and Whitehawk contributing its ADC linker-payload technologies. Under the agreement, Biocytogen will receive an upfront payment plus development, regulatory, and commercial milestone payments along with low single-digit royalties, while Whitehawk gains the option to hold global rights and full program control of any resulting BsADC candidates. The companies aim to deliver new ADC investigational new drug applications within 12-24 months.FierceBiotechWhitehawk swoops in for five ADCs via development deal with China's BiocytogenWhitehawk Therapeutics has entered a collaboration with China's Biocytogen to develop bispecific antibody-drug conjugates, evaluating five bispecific antibodies from Biocytogen's RenLite platform with options to advance candidates into its pipeline. The deal includes upfront and potential milestone payments to Biocytogen, whose CEO highlighted the company's track record including a $400 million biobucks deal with Ideaya and a $326 million pact with Sotio, both signed in 2024. Whitehawk, which pivoted from commercial-stage biopharma to preclinical biotech and already has three ADCs licensed from WuXi Biologics and Hangzhou DAC, expects to file new ADC Investigational New Drug applications within 12-24 months.